No significant prognostic value of normal precursor B-cell regeneration in paediatric acute myeloid leukaemia after induction treatment

British Journal of Haematology

Volumn 161, Issue 6, 2013, Pages 861-864

  Bras, Anne E ^a   Van den Heuvel Eibrink, Marry M ^a   Van der Sluijs Gelling, Alita J ^b   Coenen, Eva A ^a   Wind, Henk ^a   Zwaan, C Michel ^a,b   Te Marvelde, Jeroen G ^a   Van der Burg, Mirjam ^a   Gibson, Brenda ^c   Rijneveld, Anita W ^a   De Haas, Valérie ^b   Van Dongen, Jacques J M ^a   Van der Velden, Vincent H J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b DUTCH CHILDHOOD ONCOLOGY GROUP   (Netherlands)

^c ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

Author keywords

AML; B cells; MRD; Paediatric; Relapse

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE; ARTICLE; BONE MARROW; CANCER PATIENT; CHEMOTHERAPY; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; OVERALL SURVIVAL; PEDIATRICS; PRE B LYMPHOCYTE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; BONE MARROW CELLS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNOPHENOTYPING; INDUCTION CHEMOTHERAPY; INFANT; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; PHENOTYPE; PRECURSOR CELLS, B-LYMPHOID; PROGNOSIS; RECURRENCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84878487145     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12329     Document Type: Article

References (9)

1. Chantepie, S.P., Salaun, V., Parienti, J.J., Truquet, F., Macro, M., Cheze, S., Vilque, J.P. & Reman, O. (2011) Hematogones: a new prognostic factor for acute myeloblastic leukemia. Blood, 117, 1315-1318.
2. Gibson, B.E., Webb, D.K., Howman, A.J., De Graaf, S.S., Harrison, C.J., Wheatley, K. & United Kingdom Childhood Leukaemia Working Group & the Dutch Childhood Oncology Group (2011) Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial. British Journal of Haematology, 155, 366-376.
3. Kaspers, G.J. & Zwaan, C.M. (2007) Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica, 92, 1519-1532.
4. Kim, H.T. (2007) Cumulative incidence in competing risks data and competing risks regression analysis. Clinical Cancer Research, 13, 559-565.
5. Langebrake, C., Creutzig, U., Dworzak, M., Hrusak, O., Mejstrikova, E., Griesinger, F., Zimmermann, M. & Reinhardt, D. (2006) Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group. Journal of Clinical Oncology, 24, 3686-3692.
6. van Lochem, E.G., van der Velden, V.H.J., Wind, H.K., te Marvelde, J.G., Westerdaal, N.A. & van Dongen, J.J. (2004) Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: reference patterns for age-related changes and disease-induced shifts. Cytometry B Clin Cytom, 60, 1-13.
7. Noordzij, J.G., de Bruin-Versteeg, S., Verkaik, N.S., Vossen, J.M., de Groot, R., Bernatowska, E., Langerak, A.W., van Gent, D.C. & van Dongen, J.J.M. (2002) The immunophenotypic and immunogenotypic B-cell differentiation arrest in bone marrow of RAG-deficient SCID patients corresponds to residual recombination activities of mutated RAG proteins. Blood, 100, 2145-2152.
8. Rubnitz, J.E., Inaba, H., Dahl, G., Ribeiro, R.C., Bowman, W.P., Taub, J., Pounds, S., Razzouk, B.I., Lacayo, N.J., Cao, X., Meshinchi, S., Degar, B., Airewele, G., Raimondi, S.C., Onciu, M., Coustan-Smith, E., Downing, J.R., Leung, W., Pui, C.H. & Campana, D. (2010) Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncology, 11, 543-552.
9. van der Velden, V.H.J., van der Sluijs-Geling, A., Gibson, B.E., te Marvelde, J.G., Hoogeveen, P.G., Hop, W.C., Wheatley, K., Bierings, M.B., Schuurhuis, G.J., de Graaf, S.S., van Wering, E.R. & van Dongen, J.J.M. (2010) Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. Leukemia, 24, 1599-1606.